FDA okays jaw-tracking gadgets to diagnose sleep apnea
Published Date: 4/22/2026
Rule
Summary
The FDA is officially classifying devices that test sleep apnea by tracking jaw movement as Class II, meaning they have special safety rules but fewer hurdles than before. This change helps companies bring these devices to patients faster and safer, starting April 22, 2026, with the classification retroactive to January 7, 2022. Sleep apnea patients and device makers will benefit from easier access and clearer guidelines without extra costs.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Device moved to Class II, speeds access
The FDA classified sleep-apnea testing devices that track jaw (mandibular) movement as Class II with special controls, effective April 22, 2026, and the classification is applicable retroactively to January 7, 2022. FDA says this lower classification will reduce regulatory burdens and enhance patient access to these devices.
Creates predicate for future devices
By classifying this device type via the De Novo process, FDA allows devices of this type to serve as predicates for future products, letting later makers use the less-burdensome 510(k) pathway instead of De Novo or PMA. That change makes it easier for companies to bring similar mandibular-movement sleep apnea devices to market.
New safety, testing, and labeling controls
The order requires special controls for these devices, including representative clinical data comparing performance to a clinical comparator, biocompatibility testing, electromagnetic/electrical safety testing, software verification and validation, and specific labeling (what is measured, warnings, interpretation guidance, and expected performance). These controls are intended to reduce risks like incorrect results or device malfunction.
Device restricted to prescription use
FDA identifies the device as a prescription device intended to aid evaluation of sleep apnea and states it is not a substitute for full polysomnography or an apnea monitor. That means you must have a prescription from a clinician to use one of these devices.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-07861, Medical Devices; Ophthalmic Devices; Classification of the Digital Therapy Device for Amblyopia
The FDA is officially classifying the digital therapy device for amblyopia (lazy eye) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool, innovative treatment faster and safer. The new classification is effective April 22, 2026, but it’s been in effect since October 20, 2021, so manufacturers can plan ahead without surprise costs or delays.
Next: 2026-07863, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System
The FDA is officially putting the Setmelanotide Eligibility Gene Variant Detection System into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also making it simpler for patients to get access to this cool new technology. The new rules took effect on April 22, 2026, but the classification applies retroactively to January 21, 2022, with no extra costs expected.